Pathogen News and Research

RSS

Novel single-particle digital assay using plasmonic nanobubbles

An interdisciplinary team from the University of Texas applied DIAMOND to the respiratory syncytial virus (RSV) diagnostics and demonstrated that DIAMOND is 150 times more sensitive than commercial lateral flow assays. They found that the measurements are completed within 2 minutes. The results of this study are published on the medRxiv* preprint server.

25 Feb 2021

SARS-CoV-2 does not infect the entire body in the same way, finds study

COVID-19, the disease caused by the pandemic coronavirus SARS-CoV-2, is primarily regarded as a respiratory infection. Yet the virus has also become known for affecting other parts of the body in ways not as well understood, sometimes with longer-term consequences, such as heart arrhythmia, fatigue and "brain fog."

24 Feb 2021

Basigin does not facilitate SARS-CoV-2 entry, say researchers

Researchers investigated the significance of a transmembrane glycoprotein basigin, or CD147, as a host cell co-receptor required for the entry of SARS-CoV-2. The findings reveal that recombinant human basigin does not interact with full-length spike protein or spike RBD of SARS-CoV-2.

24 Feb 2021

Study: Interbacterial toxins may contribute to bacterial genetic diversity

A toxin produced by bacteria as a defence mechanism causes mutations in target bacteria that could help them survive, according to a study published today in eLife.

23 Feb 2021

Research predicts which mammal species can spread SARS-CoV-2

Scientists worldwide are fighting to contain the ongoing COVID-19 pandemic, which has already claimed more than 2.48 million lives. Preventing spillback infections is essential to containing the pandemic. To do so, it is vital to understand the nature of the virus, i.e., its susceptibility to a range of hosts.

23 Feb 2021

MUSC physician wins $9.9 million contract to run trials for the Tuberculosis Trials Consortium

Susan Dorman, M.D., an infectious disease physician at the Medical University of South Carolina, was recently awarded a 10-year, $9.9 million contract by the Centers for Disease Control and Prevention to run trials for the Tuberculosis Trials Consortium.

23 Feb 2021

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

A team of scientists from the United States recently investigated the mutational signatures in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

23 Feb 2021

Genetic mechanism enables TB-causing bacterium to remember and rapidly respond to stress

Tuberculosis bacteria have evolved to remember stressful encounters and react quickly to future stress, according to a study by computational bioengineers at Rice University and infectious disease experts at Rutgers New Jersey Medical School (NJMS).

22 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

Superspreader events trigger emergence of novel SARS-CoV-2 variants in USA

A team of scientists from the USA and Germany has recently studied the evolution of SARS-CoV-2 in a representative set of sequences from the USA collected between 2020 and 2021. The findings reveal that the viral genome has accumulated multiple mutations over time with only occasional loss of mutation. The main driving forces behind such genetic variations include widespread infection and superspreader events.

22 Feb 2021

Disinfectants could be helping bacteria to become resistant

News-Medical speaks to Professor Robert Bragg about disinfectants and how they could be helping bacteria to become resistant.

22 Feb 2021

Cissampelos pareira L. extracts demonstrate anti-SARS-CoV-2 activity in vitro

A team of scientists from India has recently investigated the antiviral potency of a traditional medicinal plant Cissampelos pareira L. in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The findings reveal that both whole-plant extracts and bioactive compounds can inhibit SARS-CoV-2 replication by modulating estrogen receptor 1 (ESR1) activity.

21 Feb 2021

New biomarker predicts individual anti-tuberculosis treatment duration

When can tuberculosis therapy be stopped without risk of relapse? Doctors are faced with this question time and again, because the lack of detection of the tuberculosis pathogen Mycobacterium tuberculosis is no guarantee for a permanent cure of the lung infection.

20 Feb 2021